GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax

The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.